51037-30-0
51037-30-0
Chemical Structure
Acipimox
Synonym(s): K-9321
- CAS No.: 51037-30-0
- Formula:C6H6N2O3
- Molecular Weight:154.13
IUPAC Name: 5-carboxy-2-methylpyrazine 1-oxide
InChIKey: DJQOOSBJCLSSEY-UHFFFAOYSA-N
SMILES: O=C(C1=C[N+]([O-])=C(C)C=N1)O
Biological Activity: Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Acipimox | 99.58% | Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Acipimox (Standard) | ≥98% | Acipimox (Standard) is the analytical standard of Acipimox. This product is intended for research and analytical applications. Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Acipimox-d4 | Acipimox-d4 is the deuterium labeled Acipimox. Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox acutely inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Acipimox-13C2,15N2 | Acipimox-13C2,15N2 (K-9321-13C2,15N2) is 13C- and 15N-labeled Acipimox (HY-B0283). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Vestergaard ET, et, al. Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation. Br J Clin Pharmacol. 2017 Dec;83(12):2671-2677. [Content Brief]
- [2]. Wang-Fisher YL, et, al. Acipimox stimulates leptin production from isolated rat adipocytes. J Endocrinol. 2002 Aug;174(2):267-72. [Content Brief]
- [3]. Ahrén B. Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice. Acta Physiol Scand. 2001 Feb;171(2):161-7. [Content Brief]
